Cargando…

Haplotype analysis suggest that the MLH1 c.2059C > T mutation is a Swedish founder mutation

Lynch syndrome (LS) predisposes to a spectrum of cancers and increases the lifetime risk of developing colorectal- or endometrial cancer to over 50%. Lynch syndrome is dominantly inherited and is caused by defects in DNA mismatch-repair genes MLH1, MSH2, MSH6 or PMS2, with the vast majority detected...

Descripción completa

Detalles Bibliográficos
Autores principales:	von Salomé, Jenny, Liu, Tao, Keihäs, Markku, Morak, Moni, Holinski-Feder, Elke, Berry, Ian R., Moilanen, Jukka S., Baert-Desurmont, Stéphanie, Lindblom, Annika, Lagerstedt-Robinson, Kristina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182575/ https://www.ncbi.nlm.nih.gov/pubmed/29288294 http://dx.doi.org/10.1007/s10689-017-0067-x

Ejemplares similares

Age-Dependent Cancer Risk Is Not Different in between MSH2 and MLH1 Mutation Carriers
por: Olschwang, Sylviane, et al.
Publicado: (2009)

Haplotype Analysis of GJB2 Mutations: Founder Effect or Mutational Hot Spot?
por: Shinagawa, Jun, et al.
Publicado: (2020)

COLLABORATION AGREEMENT KE2059/TE
por: THE HENRYK NIEWODNICZANSKI INSTITUTE OF NUCLEAR PHYSICS OF THE POLISH ACADEMY OF SCIENCES, POLAND, et al.
Publicado: (2012)

Automatic delay compensation (PS/RF-LL 2059)
por: Blas, F, et al.
Publicado: (1995)

Automatic delay compensation (PS/RF-LL 2059)
por: Blas, F, et al.
Publicado: (1995)

UMD-MLH1/MSH2/MSH6 databases: description and analysis of genetic variations in French Lynch syndrome families
por: Grandval, Philippe, et al.
Publicado: (2013)

Disease-causing gene-flanking genomic rearrangements in HNPCC patients
por: Morak, Monika, et al.
Publicado: (2011)

Primary Ciliary Dyskinesia: Ancestral Haplotypes Analysis of the RSPH4A Founder Mutation in Puerto Rico
por: De Jesús-Rojas, Wilfredo, et al.
Publicado: (2021)

Haplotype analysis of the internationally distributed BRCA1 c.3331_3334delCAAG founder mutation reveals a common ancestral origin in Iberia
por: Tuazon, Anna Marie De Asis, et al.
Publicado: (2020)

Autosomal Dominant Retinal Dystrophies Caused by a Founder Splice Site Mutation, c.828+3A>T, in PRPH2 and Protein Haplotypes in trans as Modifiers
por: Shankar, Suma P., et al.
Publicado: (2016)

DFNA5 (GSDME) c.991-15_991-13delTTC: Founder Mutation or Mutational Hotspot?
por: Booth, Kevin T., et al.
Publicado: (2020)

Screening of Finnish RAD51C founder mutations in prostate and colorectal cancer patients
por: Pelttari, Liisa M, et al.
Publicado: (2012)

Haplotype defined by the MLH1-93G/A polymorphism is associated with MLH1 promoter hypermethylation in sporadic colorectal cancers
por: Miyakura, Yasuyuki, et al.
Publicado: (2014)

Evaluating the role of MLH3 p.Ser1188Ter variant in inherited breast cancer predisposition
por: Koivuluoma, Susanna, et al.
Publicado: (2019)

The first titin (c.59926 + 1G > A) founder mutation associated with dilated cardiomyopathy
por: Hoorntje, Edgar T., et al.
Publicado: (2017)

Clinical, genetic, and pathologic characterization of FKRP Mexican founder mutation c.1387A>G
por: Lee, Angela J., et al.
Publicado: (2019)

Hypertrophic cardiomyopathy in myosin-binding protein C (MYBPC3) Icelandic founder mutation carriers
por: Adalsteinsdottir, Berglind, et al.
Publicado: (2020)

Founder mutation in myosin-binding protein C with an early onset and a high penetrance in males
por: Méndez, Irene, et al.
Publicado: (2021)

First genetic characterization of Xeroderma pigmentosum in Libya: High frequency of XP‐C founder mutation
por: Khalat, Najlaa, et al.
Publicado: (2023)

Role of MAPT mutations and haplotype in frontotemporal lobar degeneration in Northern Finland
por: Kaivorinne, Anna-Lotta, et al.
Publicado: (2008)

Haplotype Analysis Reveals a Possible Founder Effect of RET Mutation R114H for Hirschsprung's Disease in the Chinese Population
por: Cornes, Belinda K., et al.
Publicado: (2010)

The frequency of BRCA1 founder mutation c.5266dupC (5382insC) in breast cancer patients from Ukraine
por: Gorodetska, Ielizaveta, et al.
Publicado: (2015)

Founder BRCA1 mutations in Nepalese population
por: Mehta, Anurag, et al.
Publicado: (2022)

Sequencing for germline mutations in Swedish breast cancer families reveals novel breast cancer risk genes
por: Helgadottir, Hafdis T., et al.
Publicado: (2021)

Recurrent and founder mutations in the Netherlands: the cardiac phenotype of DES founder mutations p.S13F and p.N342D
por: van Spaendonck-Zwarts, K. Y., et al.
Publicado: (2012)

Evaluation of the need for routine clinical testing of PALB2 c.1592delT mutation in BRCA negative Northern Finnish breast cancer families
por: Haanpää, Maria, et al.
Publicado: (2013)

An intronic mutation in MLH1 associated with familial colon and breast cancer
por: Bianchi, F., et al.
Publicado: (2010)

Gene fusions and oncogenic mutations in MLH1 deficient and BRAFV600E wild-type colorectal cancers
por: Ukkola, Iiris, et al.
Publicado: (2022)

A novel pathogenic MLH1 missense mutation, c.112A > C, p.Asn38His, in six families with Lynch syndrome
por: van Riel, Els, et al.
Publicado: (2010)

Characterization of somatic mutations of colorectal tumor in a patient with concurrent APC and MLH1 germline mutations
por: Cheng, Yunsheng, et al.
Publicado: (2023)

Colorectal cancer incidence in path_MLH1 carriers subjected to different follow-up protocols: a Prospective Lynch Syndrome Database report
por: Seppälä, Toni, et al.
Publicado: (2017)

2059. Antimicrobial Stewardship of Community Parenteral Antimicrobial Therapy: A Health System Approach
por: Buckel, Whitney R, et al.
Publicado: (2019)

How old is this mutation? - a study of three Ashkenazi Jewish founder mutations
por: Greenwood, Celia MT, et al.
Publicado: (2010)

Exonic Splicing Mutations Are More Prevalent than Currently Estimated and Can Be Predicted by Using In Silico Tools
por: Soukarieh, Omar, et al.
Publicado: (2016)

Identification of a founder BRCA2 mutation in Sardinia
por: Pisano, M, et al.
Publicado: (2000)

Evidence of a founder BRCA1 mutation in Scotland
por: Liede, A, et al.
Publicado: (2000)

Recurrent and Founder Mutations in the Netherlands: the Long-QT Syndrome
por: Hofman, N., et al.
Publicado: (2010)

BRCA1 founder mutations and ovarian cancer in Belarus
por: Savanevich, A, et al.
Publicado: (2015)

Isolated sulfite oxidase deficiency: a founder mutation
por: Mhanni, Aizeddin A., et al.
Publicado: (2020)

Correction: Exonic Splicing Mutations Are More Prevalent than Currently Estimated and Can Be Predicted by Using In Silico Tools
por: Soukarieh, Omar, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_i2dhvt9jb1uvmprg2sg11c230e